Amendments to the Specification:

Please replace paragraph [001], as amended on September 30, 2005, with the following amended paragraph:

This application is a continuation of U.S. Application No. 09/669,051, filed September 24, 2000 (now United States Patent No. 7,063,838), which claims the benefit of U.S. Provisional Application No. 60/155938, filed September 24, 1999, each of which is incorporated by reference herein in its entirety.

Please replace paragraph [0062], as amended on September 30, 2005, with the following amended paragraph:

Example 2. Determining dose dependent in vitro activity of a therapeutic agent including collagenase, elastase, and a trypsin inhibitor.

The effect of enzyme concentration on tissue digestion rates was studied (Figure 3). The "1x" tissue sample was treated with collagenase 156 Mandel units/ml + elastase 0.125 mg/ml + trypsin inhibitor 0.38 ~~mg/ml,~~ mg/ml. The "2x" sample was treated with collagenase 312 Mandel units/ml + elastase 0.25 mg/ml + trypsin inhibitor 0.76 mg/ml. The "5x" sample was treated with collagenase 780 Mandel units/ml + elastase 0.625 mg/ml + trypsin inhibitor 1.9 mg/ml. All digestion volumes were 0.5 ml. Increasing the concentration of enzymes in vitro increased the rate of tissue digestion (Figure 3). Buffer alone had no effect on the tissue. An effective in vivo dose was found to be 10,000 ABC units.